Norges Bank
CPRX

Norges Bank’s Catalyst Pharmaceutical CPRX Stock Holding History

Norges Bank’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,766
Closed -$299K – 367
2025
Q2 		$299K Hold
13,766
– – ﹤0.01% 1669
2025
Q1 		$334K Sell
13,766
-78,004
-85% -$1.76M ﹤0.01% 1709
2024
Q4 		$1.92M Hold
91,770
– – ﹤0.01% 1693
2024
Q3 		$1.82M Buy
+91,770
New +$1.7M ﹤0.01% 1667
2024
Q2 		– Sell
-120,000
Closed -$1.91M – 1949
2024
Q1 		$1.91M Buy
+120,000
New +$1.81M ﹤0.01% 1740
2023
Q1 		– Sell
-314,400
Closed -$5.85M – 2105
2022
Q4 		$5.85M Sell
314,400
-577,400
-65% -$8.89M ﹤0.01% 1731
2022
Q3 		$11.4M Buy
+891,800
New +$10.6M ﹤0.01% 1479

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank's CPRX Position: Q3 2025 in Review

Norges Bank sold out of Catalyst Pharmaceutical (CPRX) in Q3 2025, closing a stake of 13,766 shares — an estimated $299K sold.

Norges Bank first reported a position in CPRX in Q3 2022 and held it in 7 quarters. The position peaked at $11.4M in Q3 2022. 360 funds tracked by Wall St. Rank hold CPRX as of Q3 2025.

  • Norges Bank reported no remaining Catalyst Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Norges Bank sold 13,766 Catalyst Pharmaceutical shares in Q3 2025, an estimated $299K.
  • Norges Bank first reported a position in Catalyst Pharmaceutical in Q3 2022 and held it in 7 quarters.
  • Norges Bank's Catalyst Pharmaceutical position peaked at $11.4M in Q3 2022.
  • 360 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2025.

Based on Norges Bank's 13F filing for Q3 2025.